The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS
Abstract
Tumor cells evade targeted drugs by rewiring their genetic and epigenetic networks. Here, we identified that inhibition of MAPK signaling rapidly induces an epithelial-to-mesenchymal transition program by promoting re-localization of an apical-basal polarity protein, Scribble, in oncogene-addicted lung cancer models. Mis-localization of Scribble suppressed Hippo-YAP signaling, leading to YAP nuclear translocation. Furthermore, we discovered that a RAS superfamily protein MRAS is a direct target of YAP. Treatment with KRAS G12C inhibitors induced MRAS expression, which formed a complex with SHOC2, precipitating feedback activation of MAPK signaling. Abrogation of YAP activation or MRAS induction enhanced the efficacy of KRAS G12C inhibitor treatment in vivo. These results highlight a role for protein localization in the induction of a non-genetic mechanism of resistance to targeted therapies in lung cancer. Furthermore, we demonstrate that induced MRAS expression is a key mechanism of adaptive resistance following KRAS G12C inhibitor treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A mesenchymal-like differentiation state can act as a resistance mechanism to KRAS inhibitors [126,128,130].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [126]
In the citing paper
“Recent reports indicate that mislocalization of the Scribble protein leads to YAP-mediated MRAS-MAPK activation, causing adaptive resistance to KRAS-G12C inhibitors48.”
From Mechanisms of KRAS inhibitor resistance in KRAS-mutant colorectal cancer harboring Her2 amplification and aberrant KRAS localization (2025) · cites this paper as [48]
In the citing paper
“When KRAS-mutated cancer cells with a mesenchymal phenotype are treated with KRAS inhibitors, dephosphorylated YAP translocates to the nucleus and binds to TEAD. This induces transcription of downstream genes such as MRAS, leading to resistance to KRAS inhibitors [39].”
In the citing paper
“Particularly, YAP/TAZ plays a crucial role in the intrinsic and acquired resistance to inhibitors targeting RTK/MAPK pathway (24, 28–32).”
From YAP/TAZ mediates resistance to KRAS inhibitors through inhibiting proapoptosis and activating the SLC7A5/mTOR axis (2024) · cites this paper as [32]
In the citing paper
“These findings align with accumulated evidence that YAP1 is dispensable for maintaining advanced KRAS-driven tumors, which are primarily sustained by oncogenic KRAS.41,42”
From Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers (2025) · cites this paper as [41]
13 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
Dongre, A., & Weinberg, R. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0080-4 · Cited by 3,876
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
Guidelines and definitions for research on epithelial-mesenchymal transition
Yang, J., Antin, P., Berx, G., Blanpain, C., Brabletz, T., Bronner, M., Campbell, K., Cano, A., Casanova, J., Christofori, G., et al. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0237-9 · Cited by 2,226
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells
Cordenonsi, M., Zanconato, F., Azzolin, L., Forcato, M., Rosato, A., Frasson, C., Inui, M., Montagner, M., Parenti, A. R., Poletti, A., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.048 · Cited by 1,381
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
The emerging roles of YAP and TAZ in cancer
Moroishi, T., Hansen, C. G., & Guan, K.-L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3876 · Cited by 1,145
The Frequency of Ras Mutations in Cancer
Prior, I. A., Hood, F. E., & Hartley, J. L. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3682 · Cited by 1,130
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204619 · Cited by 1,061
Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985
Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716
EMT Subtype Influences Epithelial Plasticity and Mode of Cell Migration
Aiello, N. M., Maddipati, R., Norgard, R. J., Balli, D., Li, J., Yuan, S., Yamazoe, T., Black, T., Sahmoud, A., Furth, E. E., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.05.027 · Cited by 707
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Non-genetic mechanisms of therapeutic resistance in cancer
Marine, J.-C., Dawson, S.-J., & Dawson, M. A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-00302-4 · Cited by 635
de Langen, A. J., Johnson, M. L., Mazieres, J., Dingemans, A.-M. C., Mountzios, G., Pless, M., Wolf, J., Schuler, M., Lena, H., Skoulidis, F., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00221-0 · Cited by 619
Tumor adaptation and resistance to RAF inhibitors
Lito, P., Rosen, N., & Solit, D. B. (2013) · Nature Medicine · doi:10.1038/nm.3392 · Cited by 585
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551
Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., Fece de la Cruz, F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3523 · Cited by 496
Diverse alterations associated with resistance to KRAS(G12C) inhibition
Zhao, Y., Murciano-Goroff, Y. R., Xue, J. Y., Ang, A., Lucas, J., Mai, T. T., Da Cruz Paula, A. F., Saiki, A. Y., Mohn, D., Achanta, P., et al. (2021) · Nature · doi:10.1038/s41586-021-04065-2 · Cited by 479
Kurppa, K. J., Liu, Y., To, C., Zhang, T., Fan, M., Vajdi, A., Knelson, E. H., Xie, Y., Lim, K., Cejas, P., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.006 · Cited by 475
Interplay between YAP/TAZ and Metabolism
Koo, J. H., & Guan, K.-L. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.010 · Cited by 472
Protein palmitoylation and cancer
Ko, P., & Dixon, S. J. (2018) · EMBO reports · doi:10.15252/embr.201846666 · Cited by 431
A combinatorial strategy for treating KRAS-mutant lung cancer
Manchado, E., Weissmueller, S., Morris, J. P., Chen, C.-C., Wullenkord, R., Lujambio, A., de Stanchina, E., Poirier, J. T., Gainor, J. F., Corcoran, R. B., et al. (2016) · Nature · doi:10.1038/nature18600 · Cited by 403
Early events in cell adhesion and polarity during epithelial-mesenchymal transition
Huang, R. Y.-J., Guilford, P., & Thiery, J. P. (2012) · Journal of Cell Science · doi:10.1242/jcs.099697 · Cited by 369
Cell polarity and cancer – cell and tissue polarity as a non-canonical tumor suppressor
Lee, M., & Vasioukhin, V. (2008) · Journal of Cell Science · doi:10.1242/jcs.016634 · Cited by 276
KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
Misale, S., Fatherree, J. P., Cortez, E., Li, C., Bilton, S., Timonina, D., Myers, D. T., Lee, D., Gomez-Caraballo, M., Greenberg, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0368 · Cited by 259
Adachi, Y., Ito, K., Hayashi, Y., Kimura, R., Tan, T. Z., Yamaguchi, R., & Ebi, H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2077 · Cited by 249
Self-citationCo-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
Chaib, I., Karachaliou, N., Pilotto, S., Codony Servat, J., Cai, X., Li, X., Drozdowskyj, A., Servat, C. C., Yang, J., Hu, C., et al. (2017) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx014 · Cited by 210
Kaneda, A., Seike, T., Danjo, T., Nakajima, T., Otsubo, N., Yamaguchi, D., Tsuji, Y., Hamaguchi, K., Yasunaga, M., Nishiya, Y., et al. (2020) · American Journal of Cancer Research · Cited by 208
Kitai, H., Ebi, H., Tomida, S., Floros, K. V., Kotani, H., Adachi, Y., Oizumi, S., Nishimura, M., Faber, A. C., & Yano, S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1377 · Cited by 162
Self-citationFeigin, M. E., Akshinthala, S. D., Araki, K., Rosenberg, A. Z., Muthuswamy, L. B., Martin, B., Lehmann, B. D., Berman, H. K., Pietenpol, J. A., Cardiff, R. D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3415 · Cited by 135
Stephens, R., Lim, K., Portela, M., Kvansakul, M., Humbert, P. O., & Richardson, H. E. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.01.011 · Cited by 132
Young, L. C., Hartig, N., Muñoz-Alegre, M., Osés-Prieto, J. A., Durdu, S., Bender, S., Vijayakumar, V., Rudan, M. V., Gewinner, C. A., Henderson, S. R., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.10.004 · Cited by 125
ZDHHC7-mediated S-palmitoylation of Scribble regulates cell polarity
Chen, B., Zheng, B., DeRan, M., Jarugumilli, G. K., Fu, J., Brooks, Y. S., & Wu, X. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2119 · Cited by 119
Cell Type–Specific Adaptive Signaling Responses to KRASG12C Inhibition
Solanki, H. S., Welsh, E. A., Fang, B., Izumi, V., Darville, L., Stone, B., Franzese, R., Chavan, S., Kinose, F., Imbody, D., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3872 · Cited by 106
Young, L. C., Hartig, N., Boned del Río, I., Sari, S., Ringham-Terry, B., Wainwright, J. R., Jones, G. G., McCormick, F., & Rodriguez-Viciana, P. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720352115 · Cited by 98
Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers
Sulahian, R., Kwon, J. J., Walsh, K. H., Pailler, E., Bosse, T. L., Thaker, M., Almanza, D., Dempster, J. M., Pan, J., Piccioni, F., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.090 · Cited by 90
Structure–function analysis of the SHOC2–MRAS–PP1C holophosphatase complex
Kwon, J. J., Hajian, B., Bian, Y., Young, L. C., Amor, A. J., Fuller, J. R., Fraley, C. V., Sykes, A. M., So, J., Pan, J., et al. (2022) · Nature · doi:10.1038/s41586-022-04928-2 · Cited by 89
APT2 Inhibition Restores Scribble Localization and S -Palmitoylation in Snail-Transformed Cells
Hernandez, J. L., Davda, D., Kit, M. C. S., Majmudar, J. D., Won, S. J., Gang, M., Pasupuleti, S. C., Choi, A. I., Bartkowiak, C. M., & Martin, B. R. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2016.12.007 · Cited by 86
Jones, G. G., del Río, I. B., Sarı, S., Sekerim, A., Young, L. C., Hartig, N., Zubiaur, I. A., El-Bahrawy, M. A., Hynds, R. E., Lei, W., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10367-x · Cited by 84
Palmitoylated acyl protein thioesterase APT2 deforms membranes to extract substrate acyl chains
Abrami, L., Audagnotto, M., Ho, S., Marcaida, M. J., Mesquita, F. S., Anwar, M. U., Sandoz, P. A., Fonti, G., Pojer, F., Peraro, M. D., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00753-2 · Cited by 78
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
Yun, M. R., Choi, H. M., Lee, Y. W., Joo, H. S., Park, C. W., Choi, J. W., Kim, D. H., Kang, H. N., Pyo, K., Shin, E. J., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910581 · Cited by 65
Structural basis for SHOC2 modulation of RAS signalling
Liau, N. P. D., Johnson, M. C., Izadi, S., Gerosa, L., Hammel, M., Bruning, J. M., Wendorff, T. J., Phung, W., Hymowitz, S. G., & Sudhamsu, J. (2022) · Nature · doi:10.1038/s41586-022-04838-3 · Cited by 62
Structure of the SHOC2–MRAS–PP1C complex provides insights into RAF activation and Noonan syndrome
Bonsor, D. A., Alexander, P., Snead, K., Hartig, N., Drew, M. R., Messing, S. A. J., Finci, L. I., Nissley, D. V., McCormick, F. P., Esposito, D., et al. (2022) · Nature Structural & Molecular Biology · doi:10.1038/s41594-022-00841-4 · Cited by 59
Regulatory effects of post-translational modifications on zDHHC S-acyltransferases
Zmuda, F., & Chamberlain, L. H. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.014717 · Cited by 57
MRAS: A Close but Understudied Member of the RAS Family
Young, L. C., & Rodriguez-Viciana, P. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a033621 · Cited by 53
Structure of the MRAS–SHOC2–PP1C phosphatase complex
Hauseman, Z. J., Fodor, M., Dhembi, A., Viscomi, J., Egli, D., Bleu, M., Katz, S., Park, E., Jang, D. M., Porter, K. A., et al. (2022) · Nature · doi:10.1038/s41586-022-05086-1 · Cited by 52
Kota, P. B., Terrell, E. M., Ritt, D. A., Insinna, C., Westlake, C. J., & Morrison, D. K. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1805919116 · Cited by 39
Classical RAS proteins are not essential for paradoxical ERK activation induced by RAF inhibitors
Lai, L., Fer, N. D., Burgan, W. E., Wall, V. E., Xu, B., Soppet, D. R., Esposito, D., Nissley, D. V., & McCormick, F. P. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113491119 · Cited by 22
SHOC2 Is a Critical Modulator of Sensitivity to EGFR–TKIs in Non–Small Cell Lung Cancer Cells
Terai, H., Hamamoto, J., Emoto, K., Masuda, T., Manabe, T., Kuronuma, S., Kobayashi, K., Masuzawa, K., Ikemura, S., Nakayama, S., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0664 · Cited by 21
Mathieu, M.-E., Faucheux, C., Saucourt, C., Soulet, F., Gauthereau, X., Fédou, S., Trouillas, M., Thézé, N., Thiébaud, P., & Bœuf, H. (2013) · Development · doi:10.1242/dev.091082 · Cited by 16
Structure of the SHOC2–MRAS–PP1C complex provides insights into RAF activation and Noonan syndromePreprint
Bonsor, D. A., Alexander, P., Snead, K. R., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.10.491335 · Cited by 4
Cited by
Singhal, A., Li, B. T., & O’Reilly, E. M. (2024) · Nature Medicine · doi:10.1038/s41591-024-02903-0 · Cited by 332
“The Hippo pathway members YAP and TAZ have emerged as major regulators of resistance to KRAS inhibitors in recent preclinical studies 100–103 .”
Chapeau, E. A., Sansregret, L., Galli, G. G., Chène, P., Wartmann, M., Mourikis, T. P., Jaaks, P., Baltschukat, S., Barbosa, I. A. M., Bauer, D., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00754-9 · Cited by 159
“Recently, allosteric TEAD inhibitors have been used to evaluate the activity of the combination of KRAS G12C inhibitor and TEAD inhibitor 45–47 .”
A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer
Wei, D., Wang, L., Zuo, X., Maitra, A., & Bresalier, R. S. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2098 · Cited by 192
Mukhopadhyay, S., Huang, H.-Y., Lin, Z., Ranieri, M., Li, S., Sahu, S., Liu, Y., Ban, Y., Guidry, K., Hu, H., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-2729 · Cited by 105
Expected and unexpected effects after systemic inhibition of Hippo transcriptional output in cancer
Baroja, I., Kyriakidis, N. C., Halder, G. A., & Moya, I. M. (2024) · Nature Communications · doi:10.1038/s41467-024-46531-1 · Cited by 110
“YAP can promote lung cancer cell survival and therapy resistance by activating the expression of MRAS, which can reactivate MAPK signaling in the absence of KRAS G12C signaling 81 .”
Background
Metadata
- Authors
- Adachi, Y., Kimura, R., Hirade, K., Yanase, S., Nishioka, Y., Kasuga, N., Yamaguchi, R., & Ebi, H.
- Affiliations
- Aichi Cancer Center (JP)
- Aichi Cancer Center Research Institute (JP)
- Corresponding author
- Ebi, Hiromichi
- Venue
- Nature Cancer
- Published
- 2023-06-05
- Volume
- 4
- Issue
- 6
- Pages
- 829-843
- ISSN
- 2662-1347 (ISSN-L)
- OpenAlex
- W4379390412
- Semantic Scholar
- a7737aa9dac483e8dae0fc8c98e92c91a9861a8e
- Cited by
- 93
- References
- 61
- Citations by year
- 2026: 23 · 2025: 32 · 2024: 28 · 2023: 10
- FWCI
- 13.40
- Type
- journal article
- Language
- en
- Update notices
- correction (2026-10-19)
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- MEXT | Japan Society for the Promotion of Science (15KK0303)
- Japan Agency for Medical Research and Development (20cm0106513h0005)
- Princess Takamatsu Cancer Research Fund
- Takeda Science Foundation
- Aichi Cancer Center Joint Research Project on Priority Areas
- Hori Sciences and Arts Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- KRAS G12C inhibitors, adaptive drug resistance, YAP, mineralocorticoid receptor antagonists, Hippo signaling pathway, epithelial-mesenchymal transition, lung cancer, SHOC2, palmitoylation, apical-basal polarity, non-genetic resistance
- MeSH terms
- Feedback, Humans, Lung Neoplasms, Mutation, Signal Transduction, Proto-Oncogene Proteins p21(ras), ras Proteins, Intracellular Signaling Peptides and Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.